Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has approved the repurchase of up to $5 billion of the company’s common stock. Repurchases may be made at management’s discretion from time to time on the open market or through privately negotiated transactions. The repurchase program has no time limit and may be…
After meeting with Summer Infant Inc (NASDAQ:SUMR)’s new CEO, Roth Capital is highly impressed by her strategic vision and operational expertise. The firm thinks the company is poised for growth, and it keeps a Buy rating on the shares. Summer Infant, Inc. (NASDAQ:SUMR) stock performance was 12.25% in last session and finished the day at…
Geron Corporation (NASDAQ:GERN) was one of the Nasdaq’s most active movers, jumping 23 per cent to $3.20 on heavy volume after the US Food and Drug Administration lifted a partial clinical hold on a study testing its blood cancer drug. Geron Corporation (NASDAQ:GERN) stock performance was 21.15% in last session and finished the day at…
The IDIX acquisition deal tantalized ACHN investors largely because all and sundry are aware of the contention that MRK had to face during its acquisition process, with a major research based pharma company, AbbVie Inc (NYSE:ABBV) and another prime name in the healthcare industry – Johnson & Johnson (NYSE:JNJ). Johnson & Johnson (NYSE:JNJ) stock performance…
The Procter & Gamble Company (NYSE:PG), and brewers AB InBev and Greene King have all launched new products and variants recently, and although their strategies differ, each has similar goals: to achieve greater penetration among current customers or appeal to new ones. The Procter & Gamble Company (NYSE:PG) stock performance was -0.09% in last session…
Johnson & Johnson (NYSE: JNJ) has inked a global licensing deal with the privately held Aduro BioTech for developing new therapies to treat prostate cancer. According to the oncology deal, the private company granted Janssen Biotech, a division of Johnson & Johnson, the exclusive license to certain candidates specifically engineered for the treatment of prostate…
